Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.
Kim H, Xu H, George E, Hallberg D, Kumar S, Jagannathan V, Medvedev S, Kinose Y, Devins K, Verma P, Ly K, Wang Y, Greenberg RA, Schwartz L, Johnson N, Scharpf RB, Mills GB, Zhang R, Velculescu VE, Brown EJ, Simpkins F. Kim H, et al. Among authors: mills gb. Nat Commun. 2020 Jul 24;11(1):3726. doi: 10.1038/s41467-020-17127-2. Nat Commun. 2020. PMID: 32709856 Free PMC article.
p202 prevents apoptosis in murine AKR-2B fibroblasts.
Koul D, Lapushin R, Xu HJ, Mills GB, Gutterman JU, Choubey D. Koul D, et al. Among authors: mills gb. Biochem Biophys Res Commun. 1998 Jun 18;247(2):379-82. doi: 10.1006/bbrc.1998.8804. Biochem Biophys Res Commun. 1998. PMID: 9642135
Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.
Simpkins F, Hevia-Paez P, Sun J, Ullmer W, Gilbert CA, da Silva T, Pedram A, Levin ER, Reis IM, Rabinovich B, Azzam D, Xu XX, Ince TA, Yang JY, Verhaak RG, Lu Y, Mills GB, Slingerland JM. Simpkins F, et al. Among authors: mills gb. Clin Cancer Res. 2012 Nov 1;18(21):5911-23. doi: 10.1158/1078-0432.CCR-12-1257. Epub 2012 Aug 15. Clin Cancer Res. 2012. PMID: 22896656 Free PMC article.
Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours.
Ince TA, Sousa AD, Jones MA, Harrell JC, Agoston ES, Krohn M, Selfors LM, Liu W, Chen K, Yong M, Buchwald P, Wang B, Hale KS, Cohick E, Sergent P, Witt A, Kozhekbaeva Z, Gao S, Agoston AT, Merritt MA, Foster R, Rueda BR, Crum CP, Brugge JS, Mills GB. Ince TA, et al. Among authors: mills gb. Nat Commun. 2015 Jun 17;6:7419. doi: 10.1038/ncomms8419. Nat Commun. 2015. PMID: 26080861 Free PMC article.
MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.
Hew KE, Miller PC, El-Ashry D, Sun J, Besser AH, Ince TA, Gu M, Wei Z, Zhang G, Brafford P, Gao W, Lu Y, Mills GB, Slingerland JM, Simpkins F. Hew KE, et al. Among authors: mills gb. Clin Cancer Res. 2016 Feb 15;22(4):935-47. doi: 10.1158/1078-0432.CCR-15-0534. Epub 2015 Oct 19. Clin Cancer Res. 2016. PMID: 26482043 Free PMC article.
Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics.
Liu JF, Palakurthi S, Zeng Q, Zhou S, Ivanova E, Huang W, Zervantonakis IK, Selfors LM, Shen Y, Pritchard CC, Zheng M, Adleff V, Papp E, Piao H, Novak M, Fotheringham S, Wulf GM, English J, Kirschmeier PT, Velculescu VE, Paweletz C, Mills GB, Livingston DM, Brugge JS, Matulonis UA, Drapkin R. Liu JF, et al. Among authors: mills gb. Clin Cancer Res. 2017 Mar 1;23(5):1263-1273. doi: 10.1158/1078-0432.CCR-16-1237. Epub 2016 Aug 29. Clin Cancer Res. 2017. PMID: 27573169 Free PMC article.
A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers.
George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, Zhang X, Soslow R, Drapkin R, Johnson N, Zheng Y, Cotsarelis G, Nathanson KL, Simpkins F. George E, et al. Among authors: mills gb. JCI Insight. 2017 Jan 12;2(1):e89760. doi: 10.1172/jci.insight.89760. JCI Insight. 2017. PMID: 28097235 Free PMC article.
A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, Yap TA, Tripathy D, Mills GB, Meric-Bernstam F. Evans KW, et al. Among authors: mills gb. Clin Cancer Res. 2017 Nov 1;23(21):6468-6477. doi: 10.1158/1078-0432.CCR-17-0615. Clin Cancer Res. 2017. PMID: 29093017 Free PMC article.
1,134 results